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1. INTRODUCTION {#jia225586-sec-0005}
===============

In 2013, the WHO updated guidelines for prevention of mother to child transmission of HIV (PMTCT) to recommend antiretroviral treatment (ART) for pregnant or breastfeeding women living with HIV (WLWH), either during pregnancy and breast‐feeding periods only ("Option B"), or for life ("Option B+"), regardless of CD4 count. The goal was to simplify service delivery while reducing perinatal transmission in current and subsequent pregnancies, drug resistance from episodic antiretroviral exposure, maternal morbidity and mortality, and sexual transmission \[[1](#jia225586-bib-0001){ref-type="ref"}\].

Data from earlier PMTCT eras when women were offered prophylactic antiretrovirals to reduce perinatal transmission risks highlight adherence challenges during pregnant and postpartum periods \[[2](#jia225586-bib-0002){ref-type="ref"}, [3](#jia225586-bib-0003){ref-type="ref"}, [4](#jia225586-bib-0004){ref-type="ref"}, [5](#jia225586-bib-0005){ref-type="ref"}, [6](#jia225586-bib-0006){ref-type="ref"}\]. Data suggested that taking ART to support their child *and* their own health may promote improved adherence for women \[[7](#jia225586-bib-0007){ref-type="ref"}\]. More recent data after institution of Option B+, however, show low rates of viral suppression and high losses to follow‐up: for example in eSwatini 53% postpartum retention in care \[[8](#jia225586-bib-0008){ref-type="ref"}\], in Tanzania 39% viral suppression at 12 months postpartum \[[9](#jia225586-bib-0009){ref-type="ref"}\]. Follow‐up studies with tracing of women lost to specific clinic follow‐up show that some women are in care elsewhere, though overall postpartum retention in care estimates remain sub‐optimal \[[10](#jia225586-bib-0010){ref-type="ref"}\]. For women retained in care, adherence to therapy remains a challenge. In Mpumalanga Province, South Africa, self‐reported adherence to ART was 69% among pregnant WLWH \[[11](#jia225586-bib-0011){ref-type="ref"}\] and in Zimbabwe, only 40% of women were taking at least 95% of ART by pill count one year postpartum \[[12](#jia225586-bib-0012){ref-type="ref"}\]. Qualitative data from sub‐Saharan African sites suggest that adherence challenges for pregnant and postpartum WLWH relate to structural barriers to care, community and healthcare stigma, medication side effects, depression, substance use and the overwhelming challenges of poverty, gender norms, and life with a newborn \[[13](#jia225586-bib-0013){ref-type="ref"}, [14](#jia225586-bib-0014){ref-type="ref"}, [15](#jia225586-bib-0015){ref-type="ref"}, [16](#jia225586-bib-0016){ref-type="ref"}, [17](#jia225586-bib-0017){ref-type="ref"}, [18](#jia225586-bib-0018){ref-type="ref"}, [19](#jia225586-bib-0019){ref-type="ref"}, [20](#jia225586-bib-0020){ref-type="ref"}\].

To better understand adherence patterns relative to pregnancy among women initiating ART in rural, southwestern Uganda and urban South Africa in the Option B+ era, we evaluated daily ART adherence over the first year of treatment in a cohort with low losses to follow‐up. We evaluated the impact of pregnancy and postpartum follow‐up and associated factors on daily objectively measured adherence and viral suppression in two diverse African settings. Findings may inform interventions to maximize health and reproductive choice for women, infants and families.

2. METHODS {#jia225586-sec-0006}
==========

2.1. Study settings {#jia225586-sec-0007}
-------------------

In Uganda, participants were recruited from five health centres in a rural region of southwestern Uganda. Clinics included a tertiary care referral site, as well as outpatient clinics providing HIV testing and care. All are located approximately 275 km from Kampala in a largely rural area where HIV prevalence is estimated at 8% for adults and 11% among women accessing antenatal care \[[21](#jia225586-bib-0021){ref-type="ref"}\]. Option B+ for PMTCT was implemented in 2013 \[[22](#jia225586-bib-0022){ref-type="ref"}\]. Postpartum WLWH are seen together with their infants at four, six, ten and sixteen weeks, and then monthly until 18 months postpartum when women are referred to general HIV care and infants are discharged from the PMTCT clinic.

In South Africa, participants were recruited from three HIV clinics providing integrated HIV care in Gugulethu -- an urban township near Cape Town where provincial HIV prevalence is estimated at 13% for adults and 19% for women attending antenatal care \[[23](#jia225586-bib-0023){ref-type="ref"}, [24](#jia225586-bib-0024){ref-type="ref"}\]. Option B+ for PMTCT was rolled out widely in 2015 \[[25](#jia225586-bib-0025){ref-type="ref"}\] and deployed at these sites in 2013 \[[26](#jia225586-bib-0026){ref-type="ref"}\]. Per local standard of care, all women were transferred to general ART services after delivery -- either after the first routine postpartum visit or when they return for the next ART appointment after delivery.

2.2. Participants {#jia225586-sec-0008}
-----------------

Individuals were recruited between March 2015 and September 2016. Inclusion criteria included being ART‐naïve and initiating ART within one month of enrolment date, ≥18 years of age, living within 60 km of the recruitment clinic, and intending to stay in the area for the next year. Enrolled pregnant participants who were at least 34 weeks pregnant per best‐available estimates were excluded (to maximize pregnancy follow‐up time). Inability to provide informed consent was an exclusion criterion.

The parent study enrolled women with CD4 counts \<200 cells/mm^3^ and CD4 counts \>350 cells/mm^3^ for the primary study question assessing whether initial CD4 cell count (and associated immune function) influences adherence. Pregnant women were only included in the parent study if their CD4 count was at least 350 cells/mm^3^ at enrolment. Therefore, this analysis is limited to women who enrolled with CD4 count at least 350 cells/mm^3^ to reduce selection bias. Results for all participants are published elsewhere \[[27](#jia225586-bib-0027){ref-type="ref"}\].

2.3. Study procedures {#jia225586-sec-0009}
---------------------

Participants received routine care at their local clinics. Standard first‐line ART (generic tenofovir/emtricitabine/efavirenz in a combination pill) was provided by the study to avoid adherence variations due to formulation or stock outs; changes in ART were made per routine clinical guidance. Participants completed study visits at enrolment, six and twelve months and provided blood for HIV‐1 RNA (determined by the Cobas Taqman Test in Uganda and the Roche CAP/CTM HIV‐1 v2 assay in South Africa) and completed survey questionnaires. Women \<50 years of age provided urine for beta‐hCG analysis at each study visit.

Socio‐behavioural factors potentially‐relevant for adherence were chosen based on the Behavioral Model for Vulnerable Populations \[[28](#jia225586-bib-0028){ref-type="ref"}\] and included socio‐demographics, structural barriers to care (13‐item scale, scored 0 to 52, higher scores indicate more barriers \[[29](#jia225586-bib-0029){ref-type="ref"}\]), food insecurity (9‐item Household Food Insecurity Access Scale \[[30](#jia225586-bib-0030){ref-type="ref"}\], scored 0 to 27), HIV stigma (12 items adapted from the Berger HIV Stigma Scale \[[31](#jia225586-bib-0031){ref-type="ref"}\] exploring perceived negative attitudes and disclosure concerns, total scoring range 1 to 4, higher score indicating more stigma), HIV disclosure, coping (7 item scale, scoring range 1 to 4, higher score indicating more maladaptive coping \[[32](#jia225586-bib-0032){ref-type="ref"}\]), medical mistrust/conspiracy (8 item scale, scoring range 1 to 4, higher score indicating more mistrust/conspiracy \[[33](#jia225586-bib-0033){ref-type="ref"}\]), necessity and concerns about taking ART (19 item scale \[[34](#jia225586-bib-0034){ref-type="ref"}\]), clinic satisfaction (19 item scale, scoring range 1 to 4, higher score indicating more satisfaction \[[35](#jia225586-bib-0035){ref-type="ref"}\]), mental and physical health (MOS‐HIV, 35 items, scored 0 to 100, normalized with 50 indicating average health in a US population \[[36](#jia225586-bib-0036){ref-type="ref"}\]), Hopkins Symptom Checklist (HSCL) to screen for anxiety and depression (25 items, each rated 1 to 4, average score of ≥1.75 indicative of high‐risk for psychological distress \[[37](#jia225586-bib-0037){ref-type="ref"}, [38](#jia225586-bib-0038){ref-type="ref"}, [39](#jia225586-bib-0039){ref-type="ref"}\], Edinburg Postnatal Depression Score (EPDS) (10 item score, range 0 to 30 with score of ≥13 indicating positive screen for depression) \[[37](#jia225586-bib-0037){ref-type="ref"}, [40](#jia225586-bib-0040){ref-type="ref"}\] and high‐risk alcohol use (AUDIT‐C \[[41](#jia225586-bib-0041){ref-type="ref"}, [42](#jia225586-bib-0042){ref-type="ref"}\]). The degree of emotional or instrumental support (described to participants in general terms for their own interpretation) received from social network ties was assessed by using name generator questionnaires to elicit up to 20 ties, each of whom were rated for the degree of support provided to the participant \[[43](#jia225586-bib-0043){ref-type="ref"}\]. The social support score reflects the proportion of each participant's supporters who were categorized as completely supportive. Adherence was monitored with a real‐time electronic adherence monitor that transmits a date‐and‐time stamp via cellular networks for all opening events as a proxy for medication ingestion (Wisepill Technologies, Cape Town, South Africa).

2.4. Analysis {#jia225586-sec-0010}
-------------

### 2.4.1. Descriptive statistics {#jia225586-sec-0011}

Participant characteristics were summarized descriptively by study site and ever‐pregnant status. Comparisons between sites were made with Wilcoxon rank sum and Fisher's exact test for continuous and categorical variables respectively.

#### Primary predictor {#jia225586-sec-0012}

The primary predictor of interest was women's pregnancy status over 12‐month follow‐up. Follow‐up time for each woman was categorized as pregnant, postpartum or non‐pregnancy‐related. Women with positive beta‐hCG were categorized as pregnant. Women reporting a birth outcome with a date were categorized as postpartum from that date, including for pre‐term pregnancy losses. Women who were no longer pregnant by beta‐hCG testing and did not have a birth outcome reported were counted as postpartum from 40 weeks after their last menstrual period or to include a total pregnancy length of approximately 40 weeks. Once classified as postpartum, women remained postpartum through the rest of the study (no repeat pregnancies were observed). Median postpartum follow‐up time was 7.4 months (interquartile range \[IQR\], 5.5 to 8.8) in Uganda and 9.2 months (IQR, 7.6 to 11.3) in South Africa. Women without pregnancy detected or reported during follow‐up contributed to non‐pregnancy‐related time.

To test our hypothesis that adherence may differ by pregnant, postpartum and non‐pregnancy‐related status, we fitted fractional regression models with cluster‐correlated robust estimates of variance to the pooled data \[[44](#jia225586-bib-0044){ref-type="ref"}\]. ART adherence was specified as a proportion ranging from 0 to 1 inclusively. For the conditional mean model, we specified a logistic model and made no assumptions about the distribution of the model's unobserved components. Covariate selection was guided by the Theory of Vulnerable Populations \[[28](#jia225586-bib-0028){ref-type="ref"}\]. In the event that the theoretical model suggested multiple potentially collinear variables (e.g. food insecurity and socio‐economic status), we selected covariates that were most relevant based on the enrolment data. Data from women in Uganda and South Africa were analysed separately because of baseline socio‐economic and cultural differences which could affect adherence (Table [1](#jia225586-tbl-0001){ref-type="table"}). To facilitate interpretation, the estimated regression coefficients were converted to average marginal effects, or a change in adherence corresponding to a unit change in the explanatory variable of interest, with the values of all other explanatory variables as is. For continuous variables (e.g. age) the average marginal effect corresponds to the first derivative of the response with respect to the variable in question. For discrete variables (e.g. pregnancy status), the average marginal effect corresponds to a discrete change effect and is interpreted relative to the reference group; in effect, this calculation compares two hypothetical populations that have same values for the other explanatory variables in the model.

###### 

Key enrolment demographics and socio‐behavioural factors informed by the Behavioral Model for Vulnerable Populations by site and never/ever pregnant status

+------------------------------------------------------------------------+--------------------+--------------------+--------------------------------------------+----------------+----------------+----------------+--------------------------------------------------+
| Characteristic                                                         | Uganda             | South Africa       | *p* value for all Ugandan vs. all SA women |                |                |                |                                                  |
|                                                                        |                    |                    |                                            |                |                |                |                                                  |
|                                                                        | Mean (SD) or N (%) | Mean (SD) or N (%) |                                            |                |                |                |                                                  |
+========================================================================+====================+====================+============================================+================+================+================+==================================================+
| Demographics                                                           |                    |                    |                                            |                |                |                |                                                  |
+------------------------------------------------------------------------+--------------------+--------------------+--------------------------------------------+----------------+----------------+----------------+--------------------------------------------------+
| Age                                                                    | 29 (9)             | 32 (11)            | 26 (5)                                     | 31 (9)         | 35 (10)        | 27 (5)         | 0.001[\*](#jia225586-note-0002){ref-type="fn"}   |
+------------------------------------------------------------------------+--------------------+--------------------+--------------------------------------------+----------------+----------------+----------------+--------------------------------------------------+
| Pregnant at enrolment                                                  | *129 (52)*         | *--*               |                                            | *76 (40)*      | *--*           |                | 0.012[\*](#jia225586-note-0002){ref-type="fn"}   |
+------------------------------------------------------------------------+--------------------+--------------------+--------------------------------------------+----------------+----------------+----------------+--------------------------------------------------+
| Incident pregnancy during follow‐up                                    | *19 (16)*          | *--*               |                                            | *6 (5)*        | *--*           |                | 0.01[\*](#jia225586-note-0002){ref-type="fn"}    |
+------------------------------------------------------------------------+--------------------+--------------------+--------------------------------------------+----------------+----------------+----------------+--------------------------------------------------+
| Married                                                                | *143 (59)*         | *34 (34)*          | *109 (76)*                                 | *29 (15)*      | *22 (20)*      | *7 (9)*        | \<0.001[\*](#jia225586-note-0002){ref-type="fn"} |
+------------------------------------------------------------------------+--------------------+--------------------+--------------------------------------------+----------------+----------------+----------------+--------------------------------------------------+
| Highest education                                                      |                    |                    |                                            |                |                |                | \<0.001[\*](#jia225586-note-0002){ref-type="fn"} |
+------------------------------------------------------------------------+--------------------+--------------------+--------------------------------------------+----------------+----------------+----------------+--------------------------------------------------+
| None/primary                                                           | *84 (35)*          | *42 (42)*          | *42 (29)*                                  | *14 (7)*       | *9 (8)*        | *5 (6)*        |                                                  |
+------------------------------------------------------------------------+--------------------+--------------------+--------------------------------------------+----------------+----------------+----------------+--------------------------------------------------+
| Secondary                                                              | *159 (65)*         | *57 (58)*          | *102 (71)*                                 | *175 (93)*     | *99 (92)*      | *76 (94)*      |                                                  |
+------------------------------------------------------------------------+--------------------+--------------------+--------------------------------------------+----------------+----------------+----------------+--------------------------------------------------+
| Employed                                                               | *187 (77)*         | *86 (87)*          | *101 (70)*                                 | *75 (40)*      | *49 (45)*      | *26 (32)*      | \<0.001[\*](#jia225586-note-0002){ref-type="fn"} |
+------------------------------------------------------------------------+--------------------+--------------------+--------------------------------------------+----------------+----------------+----------------+--------------------------------------------------+
| Structural barrier score                                               | 29 (12)            | 3.5 (5.6)          | 2.7 (5.6)                                  | 82 (43)        | 13.3 (7.1)     | 15.0 (7.2)     | \<0.001[\*](#jia225586-note-0002){ref-type="fn"} |
+------------------------------------------------------------------------+--------------------+--------------------+--------------------------------------------+----------------+----------------+----------------+--------------------------------------------------+
| Health                                                                 |                    |                    |                                            |                |                |                |                                                  |
+------------------------------------------------------------------------+--------------------+--------------------+--------------------------------------------+----------------+----------------+----------------+--------------------------------------------------+
| Median CD4 count (cells/mL)                                            | 477 (421, 618)     | 441 (399, 485)     | 554 (438, 676)                             | 440 (394, 490) | 426 (386, 462) | 477 (413, 662) | \<0.001[\*](#jia225586-note-0002){ref-type="fn"} |
+------------------------------------------------------------------------+--------------------+--------------------+--------------------------------------------+----------------+----------------+----------------+--------------------------------------------------+
| Median HIV‐RNA (log~10~ c/mL)                                          | 3.6 (2.5, 4.3)     | 3.6 (2.6, 4.4)     | 3.6 (2.2, 4.3)                             | 4.2 (3.6, 4.6) | 4.2 (3.6, 4.8) | 4.2 (3.4, 4.5) | \<0.001[\*](#jia225586-note-0002){ref-type="fn"} |
+------------------------------------------------------------------------+--------------------+--------------------+--------------------------------------------+----------------+----------------+----------------+--------------------------------------------------+
| HIV dx greater than 30 days prior to enrolment                         | 221 (91)           | 96 (97)            | 125 (87)                                   | 138 (79)       | 96 (99)        | 42 (55)        | \<0.001[\*](#jia225586-note-0002){ref-type="fn"} |
+------------------------------------------------------------------------+--------------------+--------------------+--------------------------------------------+----------------+----------------+----------------+--------------------------------------------------+
| Median days from diagnosis to enrolment                                | 59 (4, 874)        | 285 (8, 1808)      | 34 (2.5, 420.5)                            | 40.5 (2, 730)  | 73 (22, 797)   | 1 (0, 383)     | 0.286                                            |
+------------------------------------------------------------------------+--------------------+--------------------+--------------------------------------------+----------------+----------------+----------------+--------------------------------------------------+
| Mental wellbeing                                                       | 48 (11)            | 47 (11)            | 48 (11)                                    | 38 (9)         | 39 (9)         | 38 (8)         | 0.001[\*](#jia225586-note-0002){ref-type="fn"}   |
+------------------------------------------------------------------------+--------------------+--------------------+--------------------------------------------+----------------+----------------+----------------+--------------------------------------------------+
| Physical wellbeing                                                     | 41 (5)             | 41 (4)             | 41 (5)                                     | 44 (8)         | 44 (8)         | 45 (7)         | \<0.001[\*](#jia225586-note-0002){ref-type="fn"} |
+------------------------------------------------------------------------+--------------------+--------------------+--------------------------------------------+----------------+----------------+----------------+--------------------------------------------------+
| Depressed (\>9 on EPDS)                                                | *55 (23)*          | *24 (24)*          | *31 (22)*                                  | *105 (56)*     | *65 (60)*      | *40 (49)*      | \<0.001[\*](#jia225586-note-0002){ref-type="fn"} |
+------------------------------------------------------------------------+--------------------+--------------------+--------------------------------------------+----------------+----------------+----------------+--------------------------------------------------+
| Coping score                                                           |                    | 2.2 (0.4)          | 2.2 (0.4)                                  |                | 2.4 (0.3)      | 2.3 (0.2)      |                                                  |
+------------------------------------------------------------------------+--------------------+--------------------+--------------------------------------------+----------------+----------------+----------------+--------------------------------------------------+
| Severe food insecurity                                                 | *69 (28)*          | *32 (32)*          | *37 (26)*                                  | *121 (64)*     | *68 (63)*      | *53 (65)*      | \<0.001[\*](#jia225586-note-0002){ref-type="fn"} |
+------------------------------------------------------------------------+--------------------+--------------------+--------------------------------------------+----------------+----------------+----------------+--------------------------------------------------+
| Heavy alcohol use                                                      | *19 (8)*           | *10 (10)*          | *9 (6)*                                    | *47 (25)*      | *30 (28)*      | *17 (21)*      | \<0.001[\*](#jia225586-note-0002){ref-type="fn"} |
+------------------------------------------------------------------------+--------------------+--------------------+--------------------------------------------+----------------+----------------+----------------+--------------------------------------------------+
| Medications other than ART                                             | *207 (85)*         | *90 (91)*          | *117 (81)*                                 | *25 (13)*      | *22 (20)*      | *3 (4)*        | \<0.001[\*](#jia225586-note-0002){ref-type="fn"} |
+------------------------------------------------------------------------+--------------------+--------------------+--------------------------------------------+----------------+----------------+----------------+--------------------------------------------------+
| Cigarette use                                                          | *5 (2)*            | *3 (3)*            | *2 (1)*                                    | *27 (14)*      | *16 (15)*      | *11 (14)*      | \<0.001[\*](#jia225586-note-0002){ref-type="fn"} |
+------------------------------------------------------------------------+--------------------+--------------------+--------------------------------------------+----------------+----------------+----------------+--------------------------------------------------+
| Reproductive health history                                            |                    |                    |                                            |                |                |                |                                                  |
+------------------------------------------------------------------------+--------------------+--------------------+--------------------------------------------+----------------+----------------+----------------+--------------------------------------------------+
| \# of biological children                                              | 2 (0, 3)           | 2 (1, 4)           | 1 (0, 2)                                   | 1 (1, 2)       | 2 (1, 3)       | 1 (1, 2)       | 0.27                                             |
+------------------------------------------------------------------------+--------------------+--------------------+--------------------------------------------+----------------+----------------+----------------+--------------------------------------------------+
| Estimated GA at enrolment, weeks (limited to those enrolling pregnant) | *--*               | *--*               | 19 (12, 24)                                | *--*           | *--*           | 24 (19, 28)    | \<0.001[\*](#jia225586-note-0002){ref-type="fn"} |
+------------------------------------------------------------------------+--------------------+--------------------+--------------------------------------------+----------------+----------------+----------------+--------------------------------------------------+
| Partner/relationships                                                  |                    |                    |                                            |                |                |                |                                                  |
+------------------------------------------------------------------------+--------------------+--------------------+--------------------------------------------+----------------+----------------+----------------+--------------------------------------------------+
| Relationship w/main partner                                            |                    |                    |                                            |                |                |                |                                                  |
+------------------------------------------------------------------------+--------------------+--------------------+--------------------------------------------+----------------+----------------+----------------+--------------------------------------------------+
| Spouse                                                                 | *149 (69)*         | *37 (49)*          | *112 (81)*                                 | *45 (27)*      | *30 (33)*      | *15 (19)*      | \<0.001[\*](#jia225586-note-0002){ref-type="fn"} |
+------------------------------------------------------------------------+--------------------+--------------------+--------------------------------------------+----------------+----------------+----------------+--------------------------------------------------+
| Regular                                                                | *55 (26)*          | *33 (43)*          | *22 (16)*                                  | *118 (69)*     | *55 (61)*      | *63 (79)*      |                                                  |
+------------------------------------------------------------------------+--------------------+--------------------+--------------------------------------------+----------------+----------------+----------------+--------------------------------------------------+
| Other                                                                  | *11 (5)*           | *6 (8)*            | *5 (4)*                                    | *7 (4)*        | *5 (6)*        | *2 (2)*        |                                                  |
+------------------------------------------------------------------------+--------------------+--------------------+--------------------------------------------+----------------+----------------+----------------+--------------------------------------------------+
| Main partner HIV serostatus                                            |                    |                    |                                            |                |                |                | 0.055                                            |
+------------------------------------------------------------------------+--------------------+--------------------+--------------------------------------------+----------------+----------------+----------------+--------------------------------------------------+
| Negative                                                               | *27 (13)*          | *8 (11)*           | *19 (14)*                                  | *22 (13)*      | *14 (15)*      | *8 (10)*       |                                                  |
+------------------------------------------------------------------------+--------------------+--------------------+--------------------------------------------+----------------+----------------+----------------+--------------------------------------------------+
| Positive                                                               | *78 (36)*          | *30 (39)*          | *48 (34)*                                  | *44 (25)*      | *31 (33)*      | *13 (16)*      |                                                  |
+------------------------------------------------------------------------+--------------------+--------------------+--------------------------------------------+----------------+----------------+----------------+--------------------------------------------------+
| Don't know                                                             | *110 (51)*         | *38 (50)*          | *72 (52)*                                  | *108 (57)*     | *49 (52)*      | *58 (73)*      |                                                  |
+------------------------------------------------------------------------+--------------------+--------------------+--------------------------------------------+----------------+----------------+----------------+--------------------------------------------------+
| Refused                                                                |                    | *--*‐              | *--*‐                                      |                | 0 (0)          | 1 (1)          |                                                  |
+------------------------------------------------------------------------+--------------------+--------------------+--------------------------------------------+----------------+----------------+----------------+--------------------------------------------------+
| Physical violence past six months                                      | *31 (18)*          | *12 (19)*          | *19 (17)*                                  | *6 (3)*        | *3 (3)*        | *3 (4)*        | \<0.001[\*](#jia225586-note-0002){ref-type="fn"} |
+------------------------------------------------------------------------+--------------------+--------------------+--------------------------------------------+----------------+----------------+----------------+--------------------------------------------------+
| Exchange money for sex past six months                                 | *33 (14)*          | *11 (11)*          | *22 (15)*                                  | *3 (2)*        | *1 (1)*        | *2 (3)*        | \<0.001[\*](#jia225586-note-0002){ref-type="fn"} |
+------------------------------------------------------------------------+--------------------+--------------------+--------------------------------------------+----------------+----------------+----------------+--------------------------------------------------+
| Forced sex past six months                                             | *33 (14)*          | *11 (12)*          | *22 (15)*                                  | *9 (5)*        | *7 (7)*        | *2 (3)*        | 0.002[\*](#jia225586-note-0002){ref-type="fn"}   |
+------------------------------------------------------------------------+--------------------+--------------------+--------------------------------------------+----------------+----------------+----------------+--------------------------------------------------+
| Disclosure/stigma/social support/relationship with HC system           |                    |                    |                                            |                |                |                |                                                  |
+------------------------------------------------------------------------+--------------------+--------------------+--------------------------------------------+----------------+----------------+----------------+--------------------------------------------------+
| Disclosed aside from healthcare worker                                 | *188 (77)*         | *79 (80)*          | *109 (76)*                                 | *137 (73)*     | *92 (85)*      | *45 (56)*      | 0.24                                             |
+------------------------------------------------------------------------+--------------------+--------------------+--------------------------------------------+----------------+----------------+----------------+--------------------------------------------------+
| Disclosed outside of household                                         | *123 (51)*         | *60 (61)*          | *63 (44)*                                  | *74 (39)*      | *55 (51)*      | *19 (24)*      | 0.025[\*](#jia225586-note-0002){ref-type="fn"}   |
+------------------------------------------------------------------------+--------------------+--------------------+--------------------------------------------+----------------+----------------+----------------+--------------------------------------------------+
| Stigma: perceived negative attitudes towards HIV                       | 1 (0, 4)           | 1 (0, 3)           | 2 (0, 4)                                   | 3 (0, 4)       | 3 (1, 4)       | 2 (0, 4)       | 0.032[\*](#jia225586-note-0002){ref-type="fn"}   |
+------------------------------------------------------------------------+--------------------+--------------------+--------------------------------------------+----------------+----------------+----------------+--------------------------------------------------+
| Stigma: disclosure concerns                                            | 5 (2, 6)           | 4 (1, 6)           | 5 (2, 7)                                   | 3 (1, 6)       | 3 (1, 5.5)     | 4 (1, 6)       | 0.06                                             |
+------------------------------------------------------------------------+--------------------+--------------------+--------------------------------------------+----------------+----------------+----------------+--------------------------------------------------+
| Instrumental support                                                   | 0.4 (0.2)          | 0.4 (0.2)          | 0.4 (0.2)                                  | 0.5 (0.3)      | 0.5 (0.3)      | 0.6 (0.3)      | \<0.001[\*](#jia225586-note-0002){ref-type="fn"} |
+------------------------------------------------------------------------+--------------------+--------------------+--------------------------------------------+----------------+----------------+----------------+--------------------------------------------------+
| Emotional support                                                      | 0.5 (0.3)          | 0.5 (0.3)          | 0.6 (0.3)                                  | 0.8 (0.3)      | 0.7 (0.3)      | 0.6 (0.3)      | \<0.001[\*](#jia225586-note-0002){ref-type="fn"} |
+------------------------------------------------------------------------+--------------------+--------------------+--------------------------------------------+----------------+----------------+----------------+--------------------------------------------------+
| Healthcare system/medication trust                                     |                    |                    |                                            |                |                |                |                                                  |
+------------------------------------------------------------------------+--------------------+--------------------+--------------------------------------------+----------------+----------------+----------------+--------------------------------------------------+
| Medical mistrust                                                       | 1.75 (1, 2.5)      | 1.75 (1, 2.25)     | 1.75 (1, 2.5)                              | 3 (2, 2.5)     | 2 (2, 2.5)     | 2 (2, 2.5)     | \<0.001[\*](#jia225586-note-0002){ref-type="fn"} |
+------------------------------------------------------------------------+--------------------+--------------------+--------------------------------------------+----------------+----------------+----------------+--------------------------------------------------+
| Conspiracy                                                             | 1.9 (0.7)          | 1.9 (0.7)          | 1.9 (0.7)                                  | 2.3 (2, 2.5)   | 2.3 (2, 2.7)   | 2.3 (2, 2.5)   | \<0.001[\*](#jia225586-note-0002){ref-type="fn"} |
+------------------------------------------------------------------------+--------------------+--------------------+--------------------------------------------+----------------+----------------+----------------+--------------------------------------------------+
| Clinic satisfaction                                                    | 3.5 (0.4)          | 3.5 (0.4)          | 3.5 (0.4)                                  | 3.1 (0.4)      | 3.1 (0.4)      | 3.1 (0.4)      | \<0.001[\*](#jia225586-note-0002){ref-type="fn"} |
+------------------------------------------------------------------------+--------------------+--------------------+--------------------------------------------+----------------+----------------+----------------+--------------------------------------------------+
| ART need                                                               |                    |                    |                                            |                |                |                |                                                  |
+------------------------------------------------------------------------+--------------------+--------------------+--------------------------------------------+----------------+----------------+----------------+--------------------------------------------------+
| Low                                                                    | *40 (16)*          | *17 (17)*          | *23 (16)*                                  | *87 (46)*      | *46 (43)*      | *41 (51)*      | \<0.001[\*](#jia225586-note-0002){ref-type="fn"} |
+------------------------------------------------------------------------+--------------------+--------------------+--------------------------------------------+----------------+----------------+----------------+--------------------------------------------------+
| Moderate                                                               | *94 (39)*          | *40 (40)*          | *54 (38)*                                  | *81 (43)*      | *50 (46)*      | *31 (38)*      |                                                  |
+------------------------------------------------------------------------+--------------------+--------------------+--------------------------------------------+----------------+----------------+----------------+--------------------------------------------------+
| High                                                                   | *109 (45)*         | *42 (42)*          | *67 (47)*                                  | *21 (11)*      | *12 (11)*      | *9 (11)*       |                                                  |
+------------------------------------------------------------------------+--------------------+--------------------+--------------------------------------------+----------------+----------------+----------------+--------------------------------------------------+
| ART concerns                                                           |                    |                    |                                            |                |                |                |                                                  |
+------------------------------------------------------------------------+--------------------+--------------------+--------------------------------------------+----------------+----------------+----------------+--------------------------------------------------+
| Low                                                                    | *46 (19)*          | *11 (11)*          | *35 (24)*                                  | *8 (4)*        | *4 (4)*        | *4 (5)*        | \<0.001[\*](#jia225586-note-0002){ref-type="fn"} |
+------------------------------------------------------------------------+--------------------+--------------------+--------------------------------------------+----------------+----------------+----------------+--------------------------------------------------+
| Moderate                                                               | *74 (31)*          | *41 (41)*          | *33 (23)*                                  | *67 (36)*      | *37 (34)*      | *30 (37)*      |                                                  |
+------------------------------------------------------------------------+--------------------+--------------------+--------------------------------------------+----------------+----------------+----------------+--------------------------------------------------+
| High                                                                   | *123 (51)*         | *47 (48)*          | *76 (53)*                                  | *114 (60)*     | *67 (62)*      | *47 (58)*      |                                                  |
+------------------------------------------------------------------------+--------------------+--------------------+--------------------------------------------+----------------+----------------+----------------+--------------------------------------------------+

All *p*‐values determined by Fishers exact test for categorical and Wilxocon rank sum for continuous variables between all Uganda women and all South Africa women. Values in italics are dichotomous variables listed as N (%). Remaining variables are continuous and either listed as mean (SD) or median (IQR).

Significant at *p* \< 0.05 level.
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### 2.4.2. Outcomes {#jia225586-sec-0013}

#### Adherence {#jia225586-sec-0014}

Adherence was calculated as the number of electronic adherence monitor opening events observed divided by the number of opening events expected during follow‐up. Adherence was capped at 100% per day and censored at death. Adherence for participants lost to follow‐up (LTFU), defined as no contact despite multiple attempts through 13 months after enrolment, was calculated until the device stopped transmitting data or until the last scheduled study visit -- whichever came first. Monitor opening events related to staff openings and during periods of known device malfunction were removed from the data \[[45](#jia225586-bib-0045){ref-type="ref"}\].

Adherence interruptions of seven or more days were also assessed \[[46](#jia225586-bib-0046){ref-type="ref"}\]. Adherence distributions between groups of never‐ and ever‐pregnant women were compared by the Wilcoxon rank sum test.

To compare adherence before and after the expected due date, first we visually inspected the distribution of adherence over time. To formally assess the difference in median adherence before vs. after the expected due date, we included an interaction term in the regression models.

In sensitivity analyses, we imputed adherence data for women LTFU as either \[[1](#jia225586-bib-0001){ref-type="ref"}\] mean adherence prior to loss to follow‐up or \[[2](#jia225586-bib-0002){ref-type="ref"}\] mean adherence for postpartum women with adherence data. These means were compared with the primary (non‐imputed) results via Student's t‐test.

#### HIV‐RNA suppression {#jia225586-sec-0015}

Viral suppression was defined as \<400 copies/mL. Participants were defined to be viraemic if they died (any cause). Those LTFU or who had missed visits and had \<80% adherence in the month prior to the missed visit were counted as viraemic.

All analyses were conducted in Stata 13 (StataCorp., College Station, TX, USA).

### 2.4.3. Ethics {#jia225586-sec-0016}

This study was approved by the human research ethics committees of Partners Healthcare, Mbarara University of Science and Technology, and the University of Cape Town. Additional regulatory approvals were secured from the Uganda National Council for Science and Technology and the Western Cape province in South Africa.

3. RESULTS {#jia225586-sec-0017}
==========

3.1. Demographics {#jia225586-sec-0018}
-----------------

This analysis includes 247 women in Uganda and 190 women in South Africa. In Uganda, 129 (39%) women were pregnant at enrolment and an additional 19 (6%) women had pregnancies over the course of follow‐up. Participants in Uganda contributed 676 months of pregnancy follow‐up time, 900 months of postpartum follow‐up time and 1274 months of non‐pregnancy‐related follow‐up time. At enrolment, Ugandan women had a mean age of 29 years (standard deviation (SD), 9); 59% were married. Most (77%) reported formal or informal employment with 28% reporting severe food insecurity but a low structural barrier score (median 0). Median CD4 cell count was 477 cells/mm^3^ (IQR, 421 to 618) and most (91%) reported being diagnosed with HIV at least one month prior to enrolment. Thirty‐six percent reported a main partner living with HIV; 51% did not know their partner's serostatus. Fifty‐five (23%) met screening criteria for depression by HSCL, 30 (30%) met screening criteria by EPDS and 19 (8%) reported heavy alcohol use. (Table [1](#jia225586-tbl-0001){ref-type="table"}).

In South Africa, 76 (26%) women were pregnant at enrolment and an additional 6 (2%) women had pregnancies during follow‐up. Participants contributed 259 months of pregnancy follow‐up time, 624 months of postpartum follow‐up time and 1247 months of non‐pregnancy‐related‐follow‐up time. At enrolment, participants had a median age of 31 years (SD, 9); 15% were married. Few (40%) reported formal or informal employment with 64% reporting severe food insecurity and a high structural barrier score (median 13; IQR, 8 to 18). Median CD4 cell count was 440 cells/mm^3^ (IQR, 394 to 490) and 79% reported being diagnosed with HIV at least one month prior to enrolment. Most (61%) did not know their partner's serostatus. Over half (56%) met the screening criteria for depression by HSCL, 30 (40%) met screening criteria by EPDS and 47 (25%) reported heavy alcohol use. Ever‐pregnant women in South Africa were younger and more likely to have been diagnosed with HIV in the last 30 days. (Table [1](#jia225586-tbl-0001){ref-type="table"}).

A total of 39/437 (9%) women across both sites (15/247, 6% in Uganda and 24/190, 13% in South Africa) had incomplete data including those who were LTFU (7 in Uganda and 13 in SA), disenrolled (4 in Uganda and 11 in SA) or died (4 in Uganda). Among these 39 women, 16 women (4 in Uganda and 12 in SA) contributed no adherence data; 23 women (11 in Uganda and 12 in SA) maintained Wisepill devices contributing adherence data for a mean of 78 (SD, 97) days. For 14 women (4 in Uganda, 10 in South Africa) viral load data were missing.

3.2. Adherence {#jia225586-sec-0019}
--------------

### 3.2.1. Uganda {#jia225586-sec-0020}

In Uganda, median adherence to ART for women during pregnancy, postpartum and non‐pregnancy‐related periods was 94% (IQR, 78% to 98%), 90% (IQR, 70% to 97%), 90% (IQR, 80% to 98%) (*p* = 0.017). Figure [1](#jia225586-fig-0001){ref-type="fig"} plots adherence relative to pregnancy period follow‐up and estimated due date, demonstrating a downward trend in median adherence after due date (*p* \< 0.001). Seven‐day interruptions were rare for all women (median, 0; IQR, 0 to 1). Imputing adherence for those women LTFU as either the mean for their adherence prior to loss to follow‐up group or the mean for postpartum women LTFU but with adherence data, did not result in statistically different adherence estimates. Mean adherence was independently associated with age (average 0.98% increase in adherence per year of age; 95% CI, 0.33% to 1.62%) and CD4 cell count (average 1.01% decrease per 50 cells/mm^3^ increase in CD4 count; 95% CI, 0.08% to 1.94%) (Table [2](#jia225586-tbl-0002){ref-type="table"}).

![Average (IQR) adherence relative to due date among pregnant women living with HIV and accessing ART in Uganda and South Africa (Only women with pregnancy included in this analysis).\
Change in slope for median and 25th percentile statistically significant (*p* \< 0.001) for Uganda cohort. All slopes statistically significant (*p* \< 0.001) for the South Africa cohort.](JIA2-23-e25586-g001){#jia225586-fig-0001}

###### 

Correlates of ART adherence as measured with daily monitoring of pill cap openings among women in Uganda (a) and South Africa (b)

  Covariate                           Average marginal effect   95% CI
  ----------------------------------- ------------------------- --------------------------
  a\. Uganda                                                    
  Non‐pregnancy‐related follow‐up     *Ref*                     *Ref*
  Pregnancy follow‐up                 0.0617                    −0.0079, 0.1313
  Postpartum follow‐up                0.0074                    −0.0704, 0.0853
  **Age**                             **0.0098**                **0.0033, 0.0162**
  **CD4 cell count (per 50 cells)**   −**0.0101**               −**0.0194,** −**0.0008**
  Highest education -- secondary      0.0104                    −0.0489, 0.0696
  Structural barrier score            −0.0020                   −0.0082, 0.0042
  Perceived stigma                    −0.0145                   −0.0313, 0.0023
  Severe food insecurity              −0.0425                   −0.1128, 0.0277
  Depressed (EPDS \> 9)               0.0254                    −0.0614, 0.1122
  Alcohol abuse (AUDIT‐C)             −0.0499                   −0.1539, 0.0540
  Instrumental support                0.0033                    −0.0018, 0.0085
  Emotional support                   −0.0013                   −0.0059, 0.0033
  Main sexual partner relationship    0.0038                    −0.1000, 0.0925
  b\. South Africa                                              
  Non‐pregnancy‐related follow‐up     *Ref*.                    *Ref*.
  Pregnancy follow‐up                 0.0512                    −0.0766, 0.1791
  **Postpartum follow‐up**            −**0.2229**               −**0.3540,** −**0.0859**
  Age                                 0.0028                    −0.0054, 0.0110
  CD4 count (per 50 cells)            0.0113                    −0.0094, 0.0340
  Highest education -- secondary      −0.0276                   −0.2180, 0.1628
  Structural barrier score            0.0039                    −0.0044, 0.0121
  Perceived stigma                    0.0154                    −0.0177, 0.0484
  Severe food insecurity              −0.0389                   −0.1648, 0.0869
  Depressed (EPDS \> 9)               −0.0022                   −0.1195, 0.1150
  Alcohol abuse (AUDIT‐C)             −0.0743                   −0.2139, 0.0653
  Instrumental support                −0.0093                   −0.0215, 0.0029
  **Emotional support**               **0.0140**                **0.0022, 0.0258**
  Main sexual partner relationship    0.0126                    −0.1360, 1612

Boldface type indicates statistical significance at the *p* \< 0.05 level. The joint *p*‐value for the adjusted association between pregnancy status and adherence is 0.0102 for the Ugandan sample and \<0.0001 for the South African sample. Estimated regression coefficients have been converted to average marginal effects for ease of exposition.

John Wiley & Sons, Ltd

In Uganda, 135 (91%) and 85 (86%) of ever‐ and never‐pregnant women achieved HIV‐RNA suppression at 12 months of follow‐up. If we assume that all women LTFU or otherwise missing were in care and suppressed, then 138/148 (93%) ever pregnant women and 89/99 (89%) never‐pregnant women were virally suppressed at one‐year follow‐up (Figure [2](#jia225586-fig-0002){ref-type="fig"}).

![Percentage of women with HIV‐RNA suppression at 12 months by site and ever‐pregnant vs. never‐pregnant status](JIA2-23-e25586-g002){#jia225586-fig-0002}

### 3.2.2. South Africa {#jia225586-sec-0021}

Among South African participants, median ART adherence was 74% during pregnant periods (IQR, 31% to 96%), 40% during postpartum (IQR, 4% to 65%) and 77% during non‐pregnancy periods (IQR, 47% to 92%) (*p* \< 0.001). Daily median adherence relative to pregnancy period follow‐up and estimated due date demonstrates a downward trend after due date (*p* \< 0.001) (Figure [1](#jia225586-fig-0001){ref-type="fig"}). The median (IQR) number of seven‐day interruptions was 0 during pregnant periods (IQR, 0 to 0.6), 0.4 during postpartum (IQR, 0.1 to 0.7) and 0.2 during non‐pregnancy periods (IQR, 0 to 0.4). Imputing adherence for women LTFU as either the mean for their adherence prior to loss to follow‐up or the mean for postpartum women LTFU but with adherence data did not result in statistically different adherence estimates. Mean adherence was associated with postpartum follow‐up (average 22.3% lower adherence during postpartum compared with non‐pregnancy‐related follow‐up; 95% CI, 8.6% to 35.4%) and emotional support (average 1.4% higher adherence per unit of increased emotional support; 95% CI, 0.22% to 2.58%).

HIV‐RNA suppression was achieved by 47 (57%) and 93 (86%) of ever‐ and never‐pregnant women (Figure [2](#jia225586-fig-0002){ref-type="fig"}). If we assume that those LTFU or missing HIV‐RNA data were in care elsewhere, then up to 57 (69%) ever‐pregnant women and 99 (92%) never‐pregnant women were virally suppressed (Figure [2](#jia225586-fig-0002){ref-type="fig"}).

4. DISCUSSION {#jia225586-sec-0022}
=============

In this observational study capturing daily adherence behaviour among women enrolled with CD4 counts of ≥350 cells/mm^3^, postpartum status was independently associated with worse adherence compared to non‐pregnant status in South Africa. Postpartum women in South Africa adhered to a median of 40% of daily ART doses and only 57% of women with a pregnancy achieved HIV‐RNA suppression one year after starting ART. In adjusted models, emotional support independently affected adherence. We also observed preservation of adherence and 91% one‐year viral suppression among women with pregnancy in rural Uganda. Importantly, there were low losses to follow‐up and medications were provided by the study, highlighting challenges with daily pill taking even when women remain in care. These data indicate the importance of local context and an urgent situation in South Africa with poor adherence leading to viremia in pregnant and postpartum women.

Policy makers, clinicians and advocates hoped that simpler regimens and messages emphasizing the importance of ART to women's health would improve adherence and HIV outcomes for women. Our findings indicate ongoing challenges, particularly in the South African cohort, during the postpartum period. Daily adherence data support earlier observations: the postpartum period is fraught with challenges and serves as a "cliff" in HIV care adherence \[[16](#jia225586-bib-0016){ref-type="ref"}\]. In the current era where most women living with HIV access ART, at least half of new infections occur during breastfeeding -- including in South Africa and Uganda where nearly all pregnant WLWH access ART \[[47](#jia225586-bib-0047){ref-type="ref"}\]. While adherence counselling through pregnancy tends to focus on the health of the child, and women may focus on the goal of delivering an HIV‐uninfected child, postpartum messaging may be less clear, particularly when women do not receive postpartum‐specific HIV care. Yet viremia postpartum has dire consequences for breastfeeding infants.

Qualitative data published from this cohort described pregnancy and the postpartum state as "de‐stabilizing experiences" in which multiple factors including changes in the relationship with the father of the child (leading to poverty and lack of emotional support), inability to work and provide for oneself and physical symptoms compromise adherence \[[48](#jia225586-bib-0048){ref-type="ref"}\]. Many women are diagnosed with HIV in pregnancy (nearly half of pregnant women in the South Africa cohort were diagnosed in the month prior to study enrolment); the concomitant stigma of living with HIV and having a pregnancy may further complicate medication adherence \[[49](#jia225586-bib-0049){ref-type="ref"}, [50](#jia225586-bib-0050){ref-type="ref"}, [51](#jia225586-bib-0051){ref-type="ref"}, [52](#jia225586-bib-0052){ref-type="ref"}, [53](#jia225586-bib-0053){ref-type="ref"}, [54](#jia225586-bib-0054){ref-type="ref"}\]. Postpartum, acute worries around delivering a healthy infant may resolve after birth and change motivations for remaining on treatment or in care \[[14](#jia225586-bib-0014){ref-type="ref"}, [15](#jia225586-bib-0015){ref-type="ref"}\]. The stress of caring for a newborn can be overwhelming, leaving little time for self‐care. In South Africa, women are generally transferred from obstetric care to another clinic upon delivery, resulting in potential for losses to follow‐up, confusion, logistical challenges, and/or suboptimal support \[[17](#jia225586-bib-0017){ref-type="ref"}\] \[[26](#jia225586-bib-0026){ref-type="ref"}\].

Nine percent of women were LTFU, disenrolled or died. We were unable to trace all women and therefore some of those LTFU may have been retained in care. However, even if all women LTFU had remained in care and achieved HIV‐RNA suppression, we would still observe low rates of viral suppression among women in South Africa. Retention in HIV care remains an important issue for pregnant and postpartum women living with HIV \[[55](#jia225586-bib-0055){ref-type="ref"}, [56](#jia225586-bib-0056){ref-type="ref"}\]. In the Ugandan sites, where adherence was high and losses to follow‐up minimal, women live in rural settings where most farm and are relatively non‐mobile. In addition, WLWH remain in mother‐baby coupled clinical care until 18 months postpartum.

In South Africa, the only factor independently associated with adherence in addition to postpartum follow‐up was emotional support which may be crucial to helping women overcome structural barriers to access care or physical challenges associated with being postpartum \[[48](#jia225586-bib-0048){ref-type="ref"}\]. Details on the types of emotional support provided were not assessed in survey data, but in qualitative data, participants described the importance of reminders and encouragement to take their medication from social supports \[[48](#jia225586-bib-0048){ref-type="ref"}\]. Among women in Uganda, older age and lower baseline CD4 cell count were associated with improved adherence. Older age is a factor frequently associated with greater ART adherence perhaps related to health literacy and life stability \[[57](#jia225586-bib-0057){ref-type="ref"}, [58](#jia225586-bib-0058){ref-type="ref"}\], although this observation largely focuses on those ages \>50 years; the age range of this study was limited to those age ≤50. Studies of women taking HIV pre‐exposure prophylaxis (PrEP) observe improved adherence with increasing age in younger cohorts \[[59](#jia225586-bib-0059){ref-type="ref"}\], perhaps related to neurodevelopmental factors \[[60](#jia225586-bib-0060){ref-type="ref"}\]. A combination of both factors may be relevant in this cohort of relatively young women. Some have postulated that a lower baseline CD4 cell count and poorer health could prompt increased motivations to adhere to therapy \[[61](#jia225586-bib-0061){ref-type="ref"}, [62](#jia225586-bib-0062){ref-type="ref"}\], which may be relevant here. That said, all of the women in this analysis initiated therapy with a relatively preserved CD4 cell count (i.e. ≥350 cells/mm^3^).

Some interventions to support women to transition from PMTCT to general ART care and to retain postpartum women in ART programmes will promote emotional support in ongoing studies with peer navigators/mentor mothers \[[63](#jia225586-bib-0063){ref-type="ref"}, [64](#jia225586-bib-0064){ref-type="ref"}\] as well as increased male involvement \[[65](#jia225586-bib-0065){ref-type="ref"}\]. In addition, studies addressing structural factors showed promising results with integration of postpartum care into routine care for the child or family \[[66](#jia225586-bib-0066){ref-type="ref"}\] \[[67](#jia225586-bib-0067){ref-type="ref"}\], mHealth reminders and cash transfers \[[68](#jia225586-bib-0068){ref-type="ref"}, [69](#jia225586-bib-0069){ref-type="ref"}, [70](#jia225586-bib-0070){ref-type="ref"}, [71](#jia225586-bib-0071){ref-type="ref"}, [72](#jia225586-bib-0072){ref-type="ref"}\]. Ongoing studies will evaluate effects of mHealth strategies \[[73](#jia225586-bib-0073){ref-type="ref"}, [74](#jia225586-bib-0074){ref-type="ref"}\], reaching women with mental health challenges in pregnancy and postpartum \[[75](#jia225586-bib-0075){ref-type="ref"}, [76](#jia225586-bib-0076){ref-type="ref"}\] and adherence clubs/decentralized care \[[77](#jia225586-bib-0077){ref-type="ref"}\]. Women in different contexts will require different types of support \[[78](#jia225586-bib-0078){ref-type="ref"}, [79](#jia225586-bib-0079){ref-type="ref"}\] and an adaptive trial design \[[80](#jia225586-bib-0080){ref-type="ref"}\] may be an efficient way to evaluate strategies to combine intervention elements to support women to remain in care \[[81](#jia225586-bib-0081){ref-type="ref"}\].

This observational study has limitations. We did not follow‐up infants for perinatal transmission outcomes. Additionally, there is potential for device non‐use to influence adherence data resulting in misclassification bias. Notably, previous studies have found to be moderate correlation between electronic monitoring and drug concentration in blood \[[82](#jia225586-bib-0082){ref-type="ref"}, [83](#jia225586-bib-0083){ref-type="ref"}\], and the HIV‐RNA data in this study align with the adherence findings. Strengths include inclusion of women from urban South Africa and rural Uganda with longitudinal objective adherence measurement, HIV‐RNA, minimal losses to follow‐up and models including behavioural factors that influence adherence based on a conceptual framework.

5. CONCLUSIONS {#jia225586-sec-0023}
==============

Many WLWH struggle to remain in care and on ART during the postpartum period. For their own health and that of their infants, effective, context‐specific interventions are needed to support women in this critical period. These data suggest that interventions to provide emotional support during the postpartum period for younger women may be important.
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